April 20, 2017 09:52 AM EDT
R&D

Ab­b­Vie, Enan­ta post stel­lar hep C PhI­II da­ta, but no one is cheer­ing

John Carroll

Editor & Founder

First, the good news about new Phase III da­ta from Ab­b­Vie $AB­BV and its part­ner Enan­ta $EN­TA on their hep C com­bo for gle­capre­vir/pi­brentasvir. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Re­gen­eron buys Lon­don-based oc­u­lar biotech

A look at biotech's year of the megaround

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

A service from the Financial Times